All In Biotech

NDA 022474 · Lab Hra Pharma

Ella

Ulipristal Acetate · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Jun 24, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Aug 13, 2010

Approved uses

2

Original approval plus efficacy supplements

Registered trials

69

16 Phase 3, 3 recruiting

FAERS reports

512

456 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 20, 2026.

Ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure [see Dosage and Administration (2.1) ] . Ella is not intended for routine use as a contraceptive. Ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. Ella is not intended for routine use as a contraceptive. ( 1 )

Mechanism: When taken immediately before ovulation is to occur, ella postpones follicular rupture. The likely primary mechanism of action of ulipristal acetate for emergency contraception is therefore inhibition or delay of ovulation; however, alterations to the endometrium that may affect implantation may also contribute to efficacy.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ELLA · ULIPRISTAL ACETATE 30MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Ulipristal" as an intervention, any sponsor and status, largest first.

All 69 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • unintended pregnancy149
  • abortion spontaneous108
  • vaginal haemorrhage74
  • drug ineffective54
  • nausea39
  • pregnancy after post coital contraception36
  • abdominal pain28
  • headache27
  • dizziness26
  • exposure during pregnancy24
  • maternal exposure during pregnancy22
  • abortion induced21

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20113
201235
201312
201417
201518
201640
201772
201860
201935
202023
202121
202241
202343
202433
202536
202623

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 106 on PubMed

Sponsor: Lab Hra Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.